This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.04.083v1 48/4/700    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Riksen, N. P. Articles by Rongen, G. A. Search for Related Content PubMed PubMed Citation Articles by Riksen, N. P. Articles by Rongen, G. A.

CLINICAL RESEARCH: ISCHEMIC PRECONDITIONING

Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning

Niels P. Riksen, MD^_*,,_*, Zhigang Zhou, MD^_*, Wim J.G. Oyen, MD, PhD, Rogier Jaspers, MD, Bart P. Ramakers, MSc^_*, Rene M.H.J. Brouwer, MD, PhD, Otto C. Boerman, PhD, Neil Steinmetz, MD, PhD^||, Paul Smits, MD, PhD^_*, and Gerard A. Rongen, MD, PhD^_*,

^_* Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
Department of Cardiothoracic Surgery, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
^|| North American Scientific, Theseus Imaging Division, Boston, Massachusetts.

Manuscript received February 15, 2006; revised manuscript received April 4, 2006, accepted April 10, 2006.

^_* Reprint requests and correspondence: Dr. Niels P. Riksen, Department of Pharmacology-Toxicology 149, Radboud University Nijmegen Medical Center, Geert Grooteplein 21, 6525 EZ Nijmegen, the Netherlands. (Email: N.Riksen{at}aig.umcn.nl).

OBJECTIVES: We studied whether caffeine impairs protection by ischemic preconditioning (IP) in humans.

BACKGROUND: Ischemic preconditioning is critically dependent on adenosine receptor stimulation. We hypothesize that the adenosine receptor antagonist caffeine blocks the protective effect of IP.

METHODS: In vivo ischemia-reperfusion injury was assessed in the thenar muscle by ^99mTc-annexin A5 scintigraphy. Forty-two healthy volunteers performed forearm ischemic exercise. In 24 subjects, this was preceded by a stimulus for IP. In a randomized double-blinded design, the subjects received caffeine (4 mg/kg) or saline intravenously before the experiment. At reperfusion, ^99mTc-annexin A5 was administered intravenously. Targeting of annexin was quantified by region-of-interest analysis, and expressed as percentage difference between experimental and contralateral hand. In vitro, we assessed recovery of contractile function of human atrial trabeculae, harvested during heart surgery, as functional end point of ischemia-reperfusion injury. Field-stimulated contraction was quantified at baseline and after simulated ischemia-reperfusion, in a paired approach with and without 5 min of IP, in the presence (n = 13) or absence (n = 17) of caffeine (10 mg/l).

RESULTS: Ischemic preconditioning reduced annexin targeting in the absence of caffeine (from 13 ± 3% to 7 ± 1% at 1 h, and from 19 ± 2% to 9 ± 3% at 4 h after reperfusion, p = 0.006), but not after caffeine administration (targeting 11 ± 2% and 16 ± 3% at 1 and 4 h). In vitro, IP improved post-ischemic functional recovery in the control group, but not in the caffeine group (8 ± 3% vs. –8 ± 5%, p = 0.003).

CONCLUSIONS: Caffeine abolishes IP in 2 human models at a dose equivalent to the drinking of 2 to 4 cups of coffee. (The Effect of Caffeine on Ischemic Preconditioning; http://clinicaltrials.gov/ct/show/NCT00184912?order=1; NCT00184912 [ClinicalTrials.gov] ).

Abbreviations and Acronyms   IP = ischemic preconditioning   Isch Ex = ischemic exercise

This article has been cited by other articles:

				P. Meijer, W. J.G. Oyen, D. Dekker, P. H.H. van den Broek, C. W. Wouters, O. C. Boerman, G. J. Scheffer, P. Smits, and G. A. Rongen Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 963 - 968. [Abstract] [Full Text] [PDF]

				J. N. Peart and J. P. Headrick Clinical cardioprotection and the value of conditioning responses Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720. [Abstract] [Full Text] [PDF]

				F. G. Blankenberg In Vivo Detection of Apoptosis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 81S - 95S. [Abstract] [Full Text] [PDF]

				N. P. Riksen, B. Franke, W. J.G. Oyen, G. F. Borm, P. van den Broek, O. C. Boerman, P. Smits, and G. A. Rongen Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene Eur. Heart J., May 1, 2007; 28(9): 1085 - 1091. [Abstract] [Full Text] [PDF]